SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: luis a. garcia who wrote (955)3/11/1998 10:10:00 AM
From: Henry Volquardsen  Read Replies (1) of 1115
 
I think the $64 question that needs to be answered re cash flow outlook is how quickly and how much they gain market penetration. I believe we are both safe in assuming, that given the nature of the compound, production costs should not be huge. Then, assuming they go prescription to start, the margins should be healthy. The marketing and sales needed will probably have a relatively large upfront fixed cost component, unless contracted out, so that returns will be low until at first until we get over a threshhold and then will start to accelerate. This is all of course speculative without more details regarding cost of production etc.
But I believe the key element will be how quickly we grow market penetration.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News